| Literature DB >> 7775134 |
T M Law1, P Mencel, R J Motzer.
Abstract
Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventy-nine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.Entities:
Mesh：
Substances：
Year: 1994 PMID： 7775134 DOI： 10.1007/bf00873048
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850